Neurocrine (NBIX) Stock Forecast & Price Target

Compare

1,493 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBIX Analyst Ratings

Strong Buy

21 Buy

2 Hold

0 Sell

Based on 23 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$176.43

▲(21.79% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $176.43 with a high forecast of $203.00 and a low forecast of $146.00. The average price target represents a 21.79% change from the last price of $144.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","204":"$204","129.75":"$129.8","154.5":"$154.5","179.25":"$179.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$203.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":176.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$176.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":146,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$146.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,129.75,154.5,179.25,204],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,143.21,147.80923076923077,152.40846153846155,157.0076923076923,161.60692307692307,166.20615384615385,170.8053846153846,175.4046153846154,180.00384615384615,184.6030769230769,189.2023076923077,193.80153846153846,198.40076923076924,{"y":203,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,143.21,145.76538461538462,148.32076923076923,150.87615384615384,153.43153846153848,155.9869230769231,158.5423076923077,161.0976923076923,163.65307692307692,166.20846153846153,168.76384615384615,171.31923076923078,173.8746153846154,{"y":176.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,143.21,143.42461538461538,143.63923076923078,143.85384615384615,144.06846153846155,144.28307692307692,144.49769230769232,144.7123076923077,144.9269230769231,145.14153846153846,145.35615384615386,145.57076923076923,145.78538461538463,{"y":146,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":122.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$203.00

Average Price Target$176.43

Lowest Price Target$146.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

$168

Buy

15.97%

Upside

Reiterated

11/12/25

Neurocrine's Promising Prospects: Buy Rating Backed by Osavampator's Success and Ingrezza's Revenue GrowthValuation and Risks. Our price target of $168 is based on an equally weighted composite of: (a) $197.45/ share, as a 25x multiple of taxed and diluted FY26 GAAP EPS of $9 discounted back to and (b) an NPV of $139/share (discount rate 14%, growth rate 1%). Risks to our investment thesis include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing.

Sean Laaman

Morgan Stanley

$178→$173

Buy

19.43%

Upside

Reiterated

11/11/25

Neurocrine (NBIX) Gets a Buy from Morgan StanleyWe maintain the OW rating on NBIX shares as we see upside risk to Crenessity estimates.

Sumant Kulkarni

Canaccord Genuity

$164

Buy

13.21%

Upside

Reiterated

11/11/25

Wall Street Analysts Are Bullish on Top Healthcare PicksPhase 2 results for NBI-1070770 in MDD were mixed but not surprising; reiterate BUY, $164 PT.

Yigal Nochomovitz

Citi

$203

Buy

40.14%

Upside

Reiterated

11/10/25

Neurocrine's Growth Potential and Positive Outlook Justify Buy Rating Despite SetbacksWe use a weighted average cost of capital (WACC) of 10% and a 0% terminal growth rate post 2035.

Tazeen Ahmad

Bank of America Securities

$191

Buy

31.85%

Upside

Reiterated

11/10/25

Promising Growth Prospects for Neurocrine: Buy Rating Reaffirmed Despite SetbacksWe note no data was shared in the press release and highlight this as a likely topic of discussion for the upcoming December 16 th R&D Day. Given this was a signal seeking study, we did not model standalone value for the program and make no changes to our DCF at this time. We await additional updates on pipeline expected at the company’s R&D Day. We maintain our Buy with $191 PO as we continue to be encouraged by the company’s commercial performance for Ingrezza and Crenessity. Updates on pipeline expected on December 16 th R&D Day We highlight NBIX will be hosting an R&D Day at their headquarters in 16 th (webcast and in-person). We expect to hear updates on the company’s early-stage muscarinic portfolio including NBI-‘570 (M1/M4 agonist), NBI-‘567 (M1 agonist), NBI-‘569 (M4 agonist) and NBI-‘986 (M4 antagonist).

Bryce Generon

TR | OpenAI - 4o

$165→$176

Buy

21.50%

Upside

Reiterated

11/06/25

AI Generated ArticleAI Generated Article

Ami Fadia

Needham

$184

Buy

27.02%

Upside

Reiterated

11/05/25

Analysts' Top Healthcare Picks: Seres Therapeutics (MCRB), Neurocrine (NBIX)

Evan Seigerman

BMO Capital

$124→$147

Hold

1.48%

Upside

Reiterated

11/03/25

BMO Capital Sticks to Their Hold Rating for Neurocrine (NBIX)

Anupam Rama

J.P. Morgan

$171→$179

Buy

23.57%

Upside

Reiterated

11/03/25

Neurocrine price target raised to $179 from $171 at JPMorganNeurocrine price target raised to $179 from $171 at JPMorgan

Danielle Brill

Truist Financial

$165→$172

Buy

18.74%

Upside

Reiterated

10/30/25

Truist Financial Keeps Their Buy Rating on Neurocrine (NBIX)

Myles Minter

William Blair

―

Buy

―

Reiterated

10/29/25

Neurocrine's Strong Performance and Strategic Initiatives Drive Buy Rating

Cory Kasimov

Evercore ISI

$200

Buy

38.06%

Upside

Reiterated

10/29/25

Evercore ISI Keeps Their Buy Rating on Neurocrine (NBIX)

Paul Matteis

Stifel Nicolaus

$174→$183

Buy

26.33%

Upside

Reiterated

10/29/25

Stifel Nicolaus Keeps Their Buy Rating on Neurocrine (NBIX)Neurocrine Biosciences, Inc. (NBIX, $147.38, Buy; Target $183.00) – 3Q25 Recap: Ingrezza and Crenessity Beats underscore strong report; we remain Buy rated.

David Amsellem

Piper Sandler

$175→$179

Buy

23.57%

Upside

Reiterated

10/29/25

Neurocrine (NBIX) Gets a Buy from Piper Sandler

Phil Nadeau

TD Cowen

$170→$175

Buy

20.81%

Upside

Reiterated

10/29/25

Neurocrine's Strong Q3 Performance and Growth Potential Justify Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

$168

Buy

15.97%

Upside

Reiterated

11/12/25

Sean Laaman

Morgan Stanley

$178→$173

Buy

19.43%

Upside

Reiterated

11/11/25

Neurocrine (NBIX) Gets a Buy from Morgan StanleyWe maintain the OW rating on NBIX shares as we see upside risk to Crenessity estimates.

Sumant Kulkarni

Canaccord Genuity

$164

Buy

13.21%

Upside

Reiterated

11/11/25

Wall Street Analysts Are Bullish on Top Healthcare PicksPhase 2 results for NBI-1070770 in MDD were mixed but not surprising; reiterate BUY, $164 PT.

Yigal Nochomovitz

Citi

$203

Buy

40.14%

Upside

Reiterated

11/10/25

Neurocrine's Growth Potential and Positive Outlook Justify Buy Rating Despite SetbacksWe use a weighted average cost of capital (WACC) of 10% and a 0% terminal growth rate post 2035.

Tazeen Ahmad

Bank of America Securities

$191

Buy

31.85%

Upside

Reiterated

11/10/25

Bryce Generon

TR | OpenAI - 4o

$165→$176

Buy

21.50%

Upside

Reiterated

11/06/25

AI Generated ArticleAI Generated Article

Ami Fadia

Needham

$184

Buy

27.02%

Upside

Reiterated

11/05/25

Analysts' Top Healthcare Picks: Seres Therapeutics (MCRB), Neurocrine (NBIX)

Evan Seigerman

BMO Capital

$124→$147

Hold

1.48%

Upside

Reiterated

11/03/25

BMO Capital Sticks to Their Hold Rating for Neurocrine (NBIX)

Anupam Rama

J.P. Morgan

$171→$179

Buy

23.57%

Upside

Reiterated

11/03/25

Neurocrine price target raised to $179 from $171 at JPMorganNeurocrine price target raised to $179 from $171 at JPMorgan

Danielle Brill

Truist Financial

$165→$172

Buy

18.74%

Upside

Reiterated

10/30/25

Truist Financial Keeps Their Buy Rating on Neurocrine (NBIX)

Myles Minter

William Blair

―

Buy

―

Reiterated

10/29/25

Neurocrine's Strong Performance and Strategic Initiatives Drive Buy Rating

Cory Kasimov

Evercore ISI

$200

Buy

38.06%

Upside

Reiterated

10/29/25

Evercore ISI Keeps Their Buy Rating on Neurocrine (NBIX)

Paul Matteis

Stifel Nicolaus

$174→$183

Buy

26.33%

Upside

Reiterated

10/29/25

David Amsellem

Piper Sandler

$175→$179

Buy

23.57%

Upside

Reiterated

10/29/25

Neurocrine (NBIX) Gets a Buy from Piper Sandler

Phil Nadeau

TD Cowen

$170→$175

Buy

20.81%

Upside

Reiterated

10/29/25

Neurocrine's Strong Q3 Performance and Growth Potential Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+1.38%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +1.38% per trade.

3 Months

xxx

Success Rate

13/17 ratings generated profit

Average Return

+6.36%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +6.36% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

21/28 ratings generated profit

Average Return

+10.46%

reiterated a buy rating 16 days ago

Copying Anupam Rama's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +10.46% per trade.

2 Years

xxx

Success Rate

25/27 ratings generated profit

Average Return

+19.41%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.59% of your transactions generating a profit, with an average return of +19.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NBIX has received 46 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 176.43.

Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.86 with a range of $1.34 to $2.44. The previous quarter’s EPS was $2.04. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $805.95M with a range of $760.80M to $830.00M. The previous quarter’s sales results were $794.90M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 176.43.

What is NBIX’s upside potential, based on the analysts’ average price target?

Neurocrine has 21.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBIX a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy which is based on 21 buy ratings, 2 hold ratings and 0 sell ratings.

What is Neurocrine’s price target?

The average price target for Neurocrine is 176.43. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $203.00 ,the lowest forecast is $146.00. The average price target represents 21.79% Increase from the current price of $144.86.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of NBIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Neurocrine (NBIX) Stock Forecast & Price Target

NBIX Analyst Ratings

NBIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NBIX Analyst Recommendation Trends

NBIX Financial Forecast

NBIX Earnings Forecast

NBIX Sales Forecast

NBIX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts